CClinicalTrials.gg
CompletedNCT06567028Updated Mar 26, 2025

OSPM-Enhanced AI Model to Identify Premalignant and Malignant Ocular Surface Tumors

An observational study in Performance of the Model, sponsored by Ningbo Eye Hospital. Completed at 1 site in China. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Ningbo Eye Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
150
Ages
1 Year to 100 Years
Sex
All
01

Study summary

An OSPM-enhanced deep learning model has been developed for identifying premalignant and malignant tumors using data retrospectively collected from the Ningbo Eye Hospital, Jiangdong Eye Hospital, and the Eye Hospital of Wenzhou Medical University. To further substantiate the model's effectiveness, we intend to evaluate it prospectively at Ningbo Eye Hospital.

02

Conditions studied

  • Performance of the Model
03

In context

Precancerous Conditions

254 studies on the registry are indexed under Precancerous Conditions; 28 are open to participants now.

This study's enrollment of 150 is close to the median of 160 across 64 observational studies indexed under Precancerous Conditions.

Browse Precancerous Conditions studies →

Lead sponsor

Ningbo Eye Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Child, Adult, Older Adult

Inclusion criteria

● Ocular surface tumor images with histopathological findings

Exclusion criteria

Exclusion Criteria:

● Low-quality images

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
150 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testOSPM-Enhanced AI Model

    Analyze tumor images using the model developed in our study

06

What researchers measure

Primary outcomes

  1. AUROC

    area under the receiver operating characteristic curve

    Time frame: 3 months

07

Study locations

1 site
  • Ningbo Eye Hospital
    Ningbo, Zhejiang 315040, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567028
Lead sponsor
Ningbo Eye Hospital
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Jun 1, 2024
Primary completion
Oct 1, 2024
Completion
Nov 1, 2024
Last update
Mar 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion